Abatacept for giant cell arteritis treatment
Treatments studied
Part of Brain & nervous system, Heart & circulation, Immune system & allergy, Skin clinical trials.
This Phase 3 trial tests abatacept to treat giant cell arteritis (GCA), a blood vessel inflammation that can cause headaches and vision risk. It’s for people with newly diagnosed or returning (relapsing) GCA with active symptoms in the last 8 weeks.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with giant cell arteritis (new or returning).
- Your GCA symptoms are active within the past 8 weeks.
- You can follow the study plan and attend all follow-up visits.
- If you could become pregnant, you must use reliable birth control during the study.
- You must be able to sign written informed consent.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests how well a special MRI (picture scan) can evaluate giant cell arteritis when it’s newly suspected and symptoms started recently. It may help doctors confirm the diagnosis and decide on treatment sooner by comparing MRI findings with standard testing like biopsy or ultrasound.
This study looks at changes in blood cells that may happen in giant cell arteritis (GCA), a condition that causes inflammation in blood vessels. By comparing people with GCA to healthy volunteers, researchers hope to find clues that might help diagnose or treat the disease earlier.
This study checks whether different MRI scanning details can better help doctors diagnose giant cell arteritis. If you’re being sent for an injected MRI because GCA is suspected, your scan results may help improve how future diagnoses are made.
This Phase 3 study compares how two standard steroid dose-reduction (tapering) schedules work for people with giant cell arteritis. It aims to see which taper approach controls the disease while reducing problems from long-term steroid use.
This trial tests a medicine called upadacitinib (an anti-JAK pill) for people with giant cell arteritis that affects the large arteries, especially the aorta. It is for those whose disease is active despite trying another treatment called tocilizumab, and aims to reduce inflammation and prevent damage.
This trial tests whether a drug called bosentan, which is usually used for other conditions, can help calm the inflammation in giant cell arteritis and reduce symptoms. You would take it in addition to your usual treatment, and it might help lower the dose of steroids you need.
Hear when a new Giant Cell Arteritis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.